Change in prostate specific antigen (PSA) baseline (Day 1 Cycle 1) to 12 weeks (Day 1, Cycle 4) [clinicaltrials_resource:9c211488f01da3f4f55ae2f262496441]
Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Change in prostate specific antigen (PSA) baseline (Day 1 Cycle 1) to 12 weeks (Day 1, Cycle 4) [clinicaltrials_resource:9c211488f01da3f4f55ae2f262496441]
Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
Bio2RDF identifier
9c211488f01da3f4f55ae2f262496441
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9c211488f01da3f4f55ae2f262496441
measure [clinicaltrials_vocabulary:measure]
Change in prostate specific antigen (PSA)
time frame [clinicaltrials_vocabulary:time-frame]
baseline (Day 1 Cycle 1) to 12 weeks (Day 1, Cycle 4)
description
Participants will receive oral ...... akfast and 340 mg with dinner.
identifier
clinicaltrials_resource:9c211488f01da3f4f55ae2f262496441
title
Change in prostate specific an ...... ) to 12 weeks (Day 1, Cycle 4)
@en
type
label
Change in prostate specific an ...... 11488f01da3f4f55ae2f262496441]
@en